December 01, 2021
3 min watch
Save
VIDEO: 90% of patients in clinical trial adhere to teprotumumab
You've successfully added to your alerts. You will receive an email when new content is published.
Click Here to Manage Email Alerts
Click Here to Manage Email Alerts
We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.
NEW ORLEANS — In this Healio Video Perspective from the AAO meeting, Raymond Douglas, MD, PhD, discusses results of a clinical trial examining adherence to teprotumumab and reasons for nonadherence in patients with thyroid eye disease.